Algernon Pharmaceuticals IncOTCQB:AGNPFView on Canadian Exchange
- LAST PRICE0.0520
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0446/ 100
- Ask / Lots0.0716/ 100
- Open / Previous Close--- / 0.0520
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | AGNPF |
|---|---|---|
| 09:35 ET | 500 | 0.046 |
| 10:36 ET | 1000 | 0.056 |
| 10:42 ET | 2000 | 0.052 |
Nov 4, 2024
Algernon Announces Warrant Extension, from 6:30PM ET on Monday Nov 04, 2024 by Dow Jones
6:30PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Algernon Pharmaceuticals Inc | 2.0M | --- | --- |
Company Information
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.
Contact Information
- Headquarters
- 400 - 601 WEST BROADWAYVANCOUVER, BC, Canada V5Z 4C2
- Phone
- 604-398-4175
- Fax
- 604-646-1553
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 27.3M |
Algernon Pharmaceuticals Inc does not pay a dividend. | |
Beta | -0.35 |
EPS | $-0.19 |
Book Value | $0.09 |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
